News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
169,612 Results
Type
Article (6827)
Company Profile (110)
Press Release (162675)
Section
Business (53842)
Career Advice (356)
Deals (9765)
Drug Delivery (30)
Drug Development (31982)
Employer Resources (69)
FDA (2730)
Job Trends (4144)
News (96540)
Policy (6756)
Tag
2024 BioCapital Digital (3)
2024 BioForest Digital (1)
2024 BioForest Standard (1)
2024 BioMidwest Digital (4)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (3)
2024 Biotech Bay Standard (6)
2024 Biotech Beach Digital (2)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (1)
2024 Genetown Standard (4)
2024 Lone Star Bio Digital (5)
2024 Pharm Country Digital (3)
2024 Pharm Country Standard (2)
2025 Lone Star Bio Digital (1)
2026 BioMidwest Elite (1)
2026 Biotech Bay Elite (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Elite (1)
Academia (258)
Adcomms (2)
Allergies (26)
Alliances (12280)
ALS (29)
Alzheimer's disease (384)
Antibody-drug conjugate (ADC) (53)
Approvals (2757)
Artificial intelligence (69)
Autoimmune disease (6)
Automation (1)
Bankruptcy (64)
Best Places to Work (3219)
BIOSECURE Act (14)
Biosimilars (40)
Biotechnology (72)
Bladder cancer (16)
Brain cancer (13)
Breast cancer (54)
Cancer (614)
Cardiovascular disease (36)
Career advice (306)
Career pathing (21)
CAR-T (54)
Cell therapy (131)
Cervical cancer (4)
Clinical research (27032)
Collaboration (260)
Compensation (244)
Complete response letters (8)
COVID-19 (657)
CRISPR (7)
C-suite (93)
Cystic fibrosis (25)
Data (695)
Decentralized trials (1)
Denatured (12)
Depression (15)
Diabetes (59)
Diagnostics (603)
Digital health (2)
Diversity (6)
Diversity, equity & inclusion (19)
Drug discovery (28)
Drug pricing (22)
Drug shortages (3)
Duchenne muscular dystrophy (17)
Earnings (23049)
Editorial (24)
Employer branding (10)
Employer resources (60)
Events (33823)
Executive appointments (278)
FDA (3054)
Featured Employer (20)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (191)
Gene editing (17)
Generative AI (9)
Gene therapy (64)
GLP-1 (242)
Government (725)
Guidances (15)
Healthcare (2313)
Huntington's disease (9)
IgA nephropathy (7)
Immunology and inflammation (30)
Indications (12)
Infectious disease (686)
Inflammatory bowel disease (46)
Inflation Reduction Act (6)
Influenza (7)
Intellectual property (35)
Interviews (58)
IPO (5766)
IRA (14)
Job creations (1025)
Job search strategy (261)
Kidney cancer (5)
Labor market (25)
Layoffs (128)
Leadership (12)
Legal (910)
Liver cancer (23)
Lung cancer (101)
Lymphoma (42)
Machine learning (2)
Management (23)
Manufacturing (105)
MASH (38)
Medical device (444)
Medtech (445)
Mergers & acquisitions (4225)
Metabolic disorders (214)
Multiple sclerosis (28)
NASH (8)
Neurodegenerative disease (24)
Neuropsychiatric disorders (7)
Neuroscience (544)
NextGen: Class of 2025 (980)
Non-profit (239)
Northern California (1017)
Now hiring (28)
Obesity (113)
Opinion (77)
Ovarian cancer (30)
Pain (23)
Pancreatic cancer (20)
Parkinson's disease (36)
Partnered (3)
Patents (69)
Patient recruitment (39)
Peanut (15)
People (17215)
Pharmaceutical (38)
Pharmacy benefit managers (1)
Phase I (8175)
Phase II (12462)
Phase III (9083)
Pipeline (409)
Podcasts (44)
Policy (54)
Postmarket research (510)
Preclinical (3051)
Press Release (19)
Prostate cancer (21)
Psychedelics (12)
Radiopharmaceuticals (111)
Rare diseases (96)
Real estate (1201)
Recruiting (29)
Regulatory (5693)
Reports (22)
Research institute (280)
Resumes & cover letters (40)
RNA editing (1)
RSV (10)
Schizophrenia (37)
Series A (34)
Series B (22)
Service/supplier (4)
Sickle cell disease (8)
Southern California (795)
Special edition (16)
Spinal muscular atrophy (43)
Sponsored (5)
Startups (958)
State (1)
Stomach cancer (1)
Supply chain (14)
The Weekly (31)
United States (7543)
Vaccines (156)
Venture capitalists (16)
Webinars (7)
Weight loss (56)
Women's health (7)
Worklife (11)
Date
Today (46)
Last 7 days (235)
Last 30 days (937)
Last 365 days (11990)
2025 (2809)
2024 (12552)
2023 (14345)
2022 (16202)
2021 (17842)
2020 (15213)
2019 (10001)
2018 (7149)
2017 (8948)
2016 (7308)
2015 (9302)
2014 (7062)
2013 (5085)
2012 (4915)
2011 (4844)
2010 (4810)
Location
Africa (165)
Alabama (18)
Arizona (18)
Arkansas (2)
Asia (13526)
Australia (1480)
California (2108)
Canada (493)
China (301)
Colorado (77)
Connecticut (89)
Delaware (69)
Europe (24466)
Florida (260)
Georgia (68)
Idaho (3)
Illinois (100)
India (7)
Indiana (77)
Iowa (5)
Japan (56)
Kansas (50)
Kentucky (7)
Maine (2)
Maryland (226)
Massachusetts (1676)
Michigan (35)
Minnesota (74)
Missouri (16)
Nebraska (6)
Nevada (4)
New Hampshire (4)
New Jersey (762)
New Mexico (7)
New York (711)
North Carolina (345)
Northern California (1017)
Ohio (65)
Oklahoma (4)
Oregon (12)
Pennsylvania (386)
Puerto Rico (5)
Rhode Island (7)
South America (210)
Southern California (795)
Tennessee (8)
Texas (209)
Utah (48)
Virginia (37)
Washington D.C. (12)
Washington State (142)
Wisconsin (9)
169,612 Results for "mereo biopharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Mereo BioPharma Reports Full Year 2024 Financial Results and Provides Corporate Highlights
March 27, 2025
·
11 min read
Press Releases
Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Healthcare Conference
March 5, 2025
·
4 min read
Press Releases
Mereo BioPharma Provides Update on Lead Clinical Programs
January 13, 2025
·
7 min read
Press Releases
Mereo BioPharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 7, 2025
·
4 min read
Business
Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the first quarter ended March 31, 2024, and provided an update on recent corporate highlights.
May 15, 2024
·
13 min read
Mereo BioPharma to Participate in Fireside Chat at the Jefferies Global Healthcare Conference
Mereo BioPharma Group plc today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a Fireside Chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 11:00am ET / 04:00pm BST.
May 30, 2024
·
5 min read
Press Releases
Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference
November 14, 2024
·
5 min read
Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market
Mereo BioPharma Group plc, a clinical-stage biopharmaceutical company focused on rare diseases, announced the pricing of an underwritten offering of 12,531,300 of its American Depositary Shares.
June 14, 2024
·
6 min read
Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Biopharma Conference
Mereo BioPharma Group plc announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a Fireside Chat at the Leerink Partners Global Biopharma Conference on Tuesday, March 12, 2024 at 11:20am ET / 03:20pm GMT.
March 5, 2024
·
5 min read
Business
Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the full year ended December 31, 2023, and provided an update on recent corporate highlights.
March 27, 2024
·
17 min read
1 of 16,962
Next
